Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study.

MLA

Van Laethem, Jean-Luc, et al. “Adjuvant Gemcitabine Alone versus Gemcitabine-Based Chemoradiotherapy after Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 28, no. 29, Oct. 2010, pp. 4450–56. EBSCOhost, https://doi.org/10.1200/JCO.2010.30.3446.

APA

Van Laethem, J.-L., Hammel, P., Mornex, F., Azria, D., Van Tienhoven, G., Vergauwe, P., Peeters, M., Polus, M., Praet, M., Mauer, M., Collette, L., Budach, V., Lutz, M., Van Cutsem, E., & Haustermans, K. (2010). Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 28(29), 4450–4456. https://doi.org/10.1200/JCO.2010.30.3446

Chicago

Van Laethem, Jean-Luc, Pascal Hammel, Françoise Mornex, David Azria, Geertjan Van Tienhoven, Philippe Vergauwe, Marc Peeters, et al. 2010. “Adjuvant Gemcitabine Alone versus Gemcitabine-Based Chemoradiotherapy after Curative Resection for Pancreatic Cancer: A Randomized EORTC-40013-22012/FFCD-9203/GERCOR Phase II Study.” Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology 28 (29): 4450–56. doi:10.1200/JCO.2010.30.3446.